Cargando…
Recognizing that Evidence is Made, not Born
Therapeutic product development, licensing and reimbursement may seem a well‐oiled machine, but continuing high attrition rates, regulatory refusals, and patients’ access issues suggest otherwise; despite serious efforts, gaps persist between stakeholders’ stated evidence requirements and actual evi...
Autores principales: | Lim, Robyn, Lee, David K., Sabourin, Pierre, Ferguson, John, Metcalf, Marilyn, Smith, Meredith, Corriol‐Rohou, Solange, Eichler, Hans‐Georg, Lumpkin, Murray, Hirsch, Gigi, Chen, Inhua Muijrers, O'Rourke, Brian, Schiel, Anja, Crabb, Nick, Aronson, Naomi, Pezalla, Edmund, Boutin, Marc, Binder, Louise, Wilhelm, Linda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590384/ https://www.ncbi.nlm.nih.gov/pubmed/30472743 http://dx.doi.org/10.1002/cpt.1317 |
Ejemplares similares
-
Comparative performance of a panel of commercially available antimicrobial nanocoatings in Europe
por: Molling, Johan W, et al.
Publicado: (2014) -
Medicines Adaptive Pathways to Patients: Why, When, and How to Engage?
por: Eichler, Hans‐Georg, et al.
Publicado: (2018) -
How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement
por: Severin, Thomas, et al.
Publicado: (2020) -
Adaptive Biomedical Innovation: Evolving Our Global System to Sustainably and Safely Bring New Medicines to Patients in Need
por: Hirsch, G, et al.
Publicado: (2016) -
P05-14 LB. Analysis of virus swarms to identify vaccine immunogens with improved exposure of epitopes recognized by broadly neutralizing antibodies
por: Berman, P, et al.
Publicado: (2009)